Bayer AG BAYRY announced that it will acquire rights to the late-stage specialty cardiovascular biopharmaceutical company ...

Cytokinetics also stands to receive up to 490 million euros from Bayer, depending on certain sales milestones. The deal covers certain uses of drug candidate aficamten in hypertrophic ...